Changeflow GovPing Healthcare & Life Sciences B. Braun Issues Correction for Hemodialysis Blo...
Urgent Enforcement Amended Final

B. Braun Issues Correction for Hemodialysis Bloodlines

Favicon for www.fda.gov FDA Medical Device Recalls
Filed
Detected
Email

Summary

B. Braun Medical Inc. received FDA Class I designation for an Urgent Medical Device Correction on April 22, 2026, affecting six Streamline Airless System and B3 Low Volume Hemodialysis Bloodline models. FDA identified this as the most serious recall type — the device may cause serious injury or death if used without correction. The recall stems from a tubing resin change causing air bubbles to adhere to arterial bloodlines during treatment, with bubble formation beginning approximately 60 minutes into dialysis. As of March 20, 2026, B. Braun has not reported any serious injuries or deaths. FDA instructs affected customers to use alternate dialysis equipment when available and follow mitigation protocols when no alternative exists.

“The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction.”

FDA , verbatim from source
Published by FDA on fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Medical Device Recalls for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 16 changes logged to date.

What changed

FDA classified B. Braun Medical Inc.'s hemodialysis bloodline correction as a Class I recall on April 22, 2026 — the most serious type, indicating potential for serious injury or death. Six specific product codes are affected across two bloodline product families. The correction was necessitated by a tubing resin change that causes air bubbles to adhere to the arterial bloodline between the patient connector and blood pump during dialysis treatment, with bubble formation typically beginning approximately 60 minutes into treatment. The bubbles may cause treatment delays, machine alarms requiring operator response, less efficient treatment, or blood loss in patients where return of blood is not clinically feasible. Healthcare facilities using these hemodialysis bloodlines should obtain the correction letter from B. Braun, assess availability of alternate equipment, apply mitigation protocols if alternatives are unavailable, ensure all relevant personnel are informed, and post the correction notice at storage locations.

What to do next

  1. Use alternate dialysis equipment
  2. Ensure full adherence to both the bloodline and dialysis machine Instructions for Use
  3. Avoid high flow during treatment if small air bubbles are present
  4. Avoid retrograde rinseback if small air bubbles are present
  5. Ensure all users and relevant personnel are informed of this correction
  6. Post the Urgent Medical Device Correction notice where the affected products are stored
  7. Contact B. Braun Medical Inc. at Recalls@bbraunusa.com or 1-833-425-1464

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.


This recall **involves correcting certain devices, and does not involve removing them from where they are used or sold.* The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction. The affected products and recommendations for what to do with the devices below have not changed.*

Affected Product

The FDA is aware that B. Braun Medical Inc. has issued an Urgent Medical Device Correction to affected customers recommending certain Streamline Airless System Hemodialysis Bloodlines and B3 Low Volume Bloodlines only be used if no alternative is available.

Affected devices:

Material Description Unique Device Identifier - Primary Unique Device Identifier - Unit
B3-3632M3705 LOW VOL, NO CHAMBER 2.6MM PUMP SEGMENT 04046955348824 04046955348817
B3-4630M4705 LOW VOL, NO CHAMBER 4.8MM PUMP SEGMENT 04046955348848 04046955348831
SL-2000M2095DA STREAMLINE FRESENIUS FOR DAVITA 04046955776023 04046955776016
SL-2000M2095L STREAMLINE BLOODLINE LONG VERSION, FMC 04046955348909 04046955348893
SL-2010M2096 STREAMLINE BLOODLINE SET FOR DIALOG 04046964367786 04046964367779
SL-2010M2096A STREAMLINE BLOODLINE SET FOR DIALOG DR 04046955674992 04046955735280

What to Do

Use alternate dialysis equipment. If you do not have access to alternate equipment and need to administer treatment, follow the instructions below to help mitigate potential harm.

On March 19, B. Braun Medical Inc. sent all affected customers a letter recommending the following actions:

  • Ensure full adherence to both the bloodline and dialysis machine Instructions for Use
  • Avoid high flow during treatment if small air bubbles are present
  • Avoid retrograde rinseback if small air bubbles are present
  • Ensure all users and relevant personnel are informed of this correction
  • Post the Urgent Medical Device Correction notice where the affected products are stored

Reason for Correction

B. Braun Medical Inc. has preliminary testing showing that a change to the tubing resin has led to small air bubbles adhering to the inside of the arterial bloodline, in the segment between the patient connector and the blood pump. These bubbles are the result of degassing of blood on the arterial side of the blood pump due to the negative pressure within the tubing and are not being drawn into the bloodline from the external environment. With the previous tubing resin, these bubbles remained in the blood and were compressed or dissolved via the positive pressure applied post blood pump. With the new resin, these small bubbles adhere to the inside of the bloodline and may gather to form larger bubbles. This process of degassing and bubble formation normally begins approximately 60 minutes into dialysis treatment.

Air bubbles detected in the line during use may lead to a delay in treatment to replace the set and resume therapy. If the operator does not replace the set, it may result in less efficient treatment. If the safety air detector in the dialysis machine detects the bubbles, the machine will alarm and automatically stop treatment. The operator must respond to the alarm to continue treatment, which may include replacing the set and/or monitoring treatment.

Patients may experience moderate blood loss if it is not clinically feasible to return the blood in the extracorporeal circuit to the patient. In some patients, blood loss may lead to life-threatening adverse events, including death.

As of March 20, 2026, B. Braun Medical Inc. has not reported any serious injuries or deaths associated with this issue.

Device Use

Bloodline tubing sets are a collection of tubing segments and associated devices like connectors and clamps that are intended to transfer blood between a patient’s vascular access device and a hemodialyzer during hemodialysis.

Contact Information

Customers in the U.S. with adverse reactions, quality problems, or questions about this recall should contact B. Braun Medical Inc. at Recalls@bbraunusa.com or 1-833-425-1464.

Additional FDA Resources

  1. FDA Enforcement Report
  2. CDRH Medical Device Recall Database

Unique Device Identifier (UDI)

The unique device identifier (UDI) helps identify individual medical devices sold in the United States from manufacturing through distribution to patient use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified, and problems potentially corrected more quickly.

How do I report a problem?

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

Timeline of Communication Updates

Date Actions
04/22/2026 The FDA updated this communication to inform the public that this issue has been classified as a Class I Recall.
03/25/2026 The FDA issued an Early Alert communication to notify the public of a potentially high-risk device issue.
  • ## Content current as of:

04/22/2026

  • Regulated Product(s)

    • Medical Devices

Get daily alerts for FDA Medical Device Recalls

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Filed
April 22nd, 2026
Instrument
Enforcement
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Medical device makers Healthcare providers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Medical device recall response Medical device safety monitoring
Geographic scope
United States US

Taxonomy

Primary area
Medical Devices
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Healthcare Product Safety

Get alerts for this source

We'll email you when FDA Medical Device Recalls publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!